Abstract Mixed lineage leukemia 1 (MLL1, also known as MLL or KMT2A) is an important
transcription factor and histone-H3 lysine-4 (H3K4) methyltransferase. It is a master …

The Eya family of proteins (consisting of Eyas1–4 in mammals) play vital roles in
embryogenesis by regulating processes such as proliferation, migration/invasion, cellular …

Inhibition of the Menin (MEN1) and MLL (MLL1, KMT2A) interaction is a potential therapeutic
strategy for MLL-rearranged (MLL-r) leukemia. Structure-based design yielded the potent …

Recurrent chromosomal translocations involving the mixed lineage leukaemia (MLL) gene
initiate aggressive forms of leukaemia, which are often refractory to conventional therapies …

To address the impact of cellular origin on acute myeloid leukemia (AML), we generated an
inducible transgenic mouse model for MLL-AF9-driven leukemia. MLL-AF9 expression in …

Chromosomal rearrangements involving the H3K4 methyltransferase mixed-lineage
leukemia (MLL) trigger aberrant gene expression in hematopoietic progenitors and give rise …

We have developed an enhanced form of reduced representation bisulfite sequencing with
extended genomic coverage, which resulted in greater capture of DNA methylation …

T cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy.
Current intensified therapeutic protocols coincide with severe side effects, and no salvage …

SIX1 interacts with EYA to form a bipartite transcription factor essential for mammalian
development. Loss of function of this complex causes branchio-oto-renal (BOR) syndrome …

Abstract The t (6; 11)(q27; q23) is a recurrent chromosomal rearrangement that encodes the
MLLAF6 fusion oncoprotein and is observed in patients with diverse hematologic …